| Study | Exclusion reasons | Remarks | Reference(s) | ||
|---|---|---|---|---|---|
| CheckMate 032 (N3I1 vs N3), 2019 | randomized controlled trial | NIVO3 demonstrated sustained antitumor activity alone and in combination with ipilimumab. NIVO1 IPI3 provided the greatest antitumor activity of all regimens, with a manageable safety profile |
Sharma J. Clin. Oncol. 2019; 37:1608-1616 10.1200/JCO.19.00538 Sharma Lancet Oncol. 2016; 17:1590-1598 10.1016/S1470-2045(16)30496-X |
||
| CheckMate 032 (N1I3 vs N3), 2019 | randomized controlled trial | P1/2 => sequential NIVO3 demonstrated sustained antitumor activity alone and in combination with ipilimumab. NIVO1 IPI3 provided the greatest antitumor activity of all regimens, with a manageable safety profile |
Sharma J. Clin. Oncol. 2019; 37:1608-1616 10.1200/JCO.19.00538 Sharma Lancet Oncol. 2016; 17:1590-1598 10.1016/S1470-2045(16)30496-X |
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
